Posted by Michael Wonder on 18 Dec 2023
EndeavorRx, world’s first and only prescription video game treatment, secures FDA label expansion for paediatric ADHD patients aged 13-17
18 December 2023 - Akili’s clinically proven digital medicine now authorised for children 8-17, opening option to more patients as on-going stimulant shortage persists.
Akili today announced that it has received authorisation from the US FDA to expand the label for EndeavorRx from 8 to 12 year old patients with primarily inattentive or combined type ADHD who have a demonstrated attention issue to include older children aged 13-17.
